LT3039033T - Surišantys polipeptidai, turintys mutuotą karkasą - Google Patents

Surišantys polipeptidai, turintys mutuotą karkasą

Info

Publication number
LT3039033T
LT3039033T LT14755841T LT14755841T LT3039033T LT 3039033 T LT3039033 T LT 3039033T LT 14755841 T LT14755841 T LT 14755841T LT 14755841 T LT14755841 T LT 14755841T LT 3039033 T LT3039033 T LT 3039033T
Authority
LT
Lithuania
Prior art keywords
binding polypeptides
scaffold
mutated
mutated scaffold
polypeptides
Prior art date
Application number
LT14755841T
Other languages
English (en)
Inventor
Erik Nordling
Joakim Nilsson
Patrik Strömberg
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of LT3039033T publication Critical patent/LT3039033T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1044Preparation or screening of libraries displayed on scaffold proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • C12Q1/6874Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LT14755841T 2013-08-28 2014-08-28 Surišantys polipeptidai, turintys mutuotą karkasą LT3039033T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13182022 2013-08-28
PCT/EP2014/068259 WO2015028550A1 (en) 2013-08-28 2014-08-28 C5 binding polypeptides

Publications (1)

Publication Number Publication Date
LT3039033T true LT3039033T (lt) 2019-10-25

Family

ID=49034001

Family Applications (1)

Application Number Title Priority Date Filing Date
LT14755841T LT3039033T (lt) 2013-08-28 2014-08-28 Surišantys polipeptidai, turintys mutuotą karkasą

Country Status (19)

Country Link
US (2) US9982022B2 (lt)
EP (1) EP3039033B1 (lt)
JP (2) JP7138411B2 (lt)
KR (2) KR102497083B1 (lt)
CN (3) CN117964710A (lt)
AU (1) AU2014314214C1 (lt)
CA (1) CA2920005C (lt)
DK (1) DK3039033T3 (lt)
ES (1) ES2742505T3 (lt)
IL (1) IL243849A0 (lt)
LT (1) LT3039033T (lt)
MX (1) MX367423B (lt)
MY (1) MY176200A (lt)
PL (1) PL3039033T3 (lt)
PT (1) PT3039033T (lt)
RU (1) RU2714156C2 (lt)
TR (1) TR201911279T4 (lt)
WO (1) WO2015028550A1 (lt)
ZA (1) ZA201600721B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2817329T3 (pl) 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polipeptydy wiążące z c5 ludzkiego dopełniacza
AU2014230018B2 (en) 2013-03-15 2018-02-22 Affibody Ab New polypeptides
KR102446636B1 (ko) 2013-08-28 2022-09-23 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 안정한 폴리펩티드
KR102236830B1 (ko) * 2014-09-17 2021-04-06 애피바디 에이비 신규 폴리펩티드
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
EP3941581A2 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. Multivalent d-peptidic compounds for target proteins
WO2020198074A1 (en) 2019-03-22 2020-10-01 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
WO2021089695A1 (en) * 2019-11-05 2021-05-14 Affibody Ab Polypeptides
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
CA3237246A1 (en) * 2021-11-01 2023-05-04 Ipc Research, Llc Administration of c5-binding proteins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP0560807A1 (en) * 1990-11-26 1993-09-22 The Public Health Laboratory Service Board Immunoglobulin-binding proteins and recombinant dna molecules coding therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
SE9901379D0 (sv) * 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharmaceuticals Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
EP2190863B1 (en) 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2011056124A1 (en) * 2009-11-04 2011-05-12 Affibody Ab Her3 binding polypeptides
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
MY161679A (en) 2010-07-09 2017-05-15 Affibody Ab Polypeptides
JP2014502272A (ja) 2010-11-29 2014-01-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティークロマトグラフィーマトリックス
CN102127554B (zh) * 2010-12-22 2012-07-25 南京农业大学 一种日本脑炎颗粒疫苗及其制备方法和应用
US9005992B2 (en) 2011-03-18 2015-04-14 Postech Academy-Industry Foundation Immobilizing fusion protein for effective and oriented immobilization of antibody on surfaces
PL2817329T3 (pl) 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polipeptydy wiążące z c5 ludzkiego dopełniacza
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
WO2014096163A1 (en) 2012-12-19 2014-06-26 Affibody Ab New polypeptides
KR102446636B1 (ko) 2013-08-28 2022-09-23 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 안정한 폴리펩티드

Also Published As

Publication number Publication date
CA2920005C (en) 2023-11-28
AU2014314214B2 (en) 2018-07-12
EP3039033A1 (en) 2016-07-06
USRE49495E1 (en) 2023-04-18
WO2015028550A1 (en) 2015-03-05
WO2015028550A8 (en) 2015-05-21
JP7138411B2 (ja) 2022-09-16
BR112016003336A2 (pt) 2017-11-21
RU2016108976A3 (lt) 2018-04-26
MY176200A (en) 2020-07-24
AU2014314214C1 (en) 2019-01-24
JP2016535061A (ja) 2016-11-10
KR20160068744A (ko) 2016-06-15
KR20220021007A (ko) 2022-02-21
CN116987154A (zh) 2023-11-03
RU2714156C2 (ru) 2020-02-12
TR201911279T4 (tr) 2019-08-21
NZ716426A (en) 2021-10-29
IL243849A0 (en) 2016-04-21
PT3039033T (pt) 2019-09-06
PL3039033T3 (pl) 2020-01-31
ZA201600721B (en) 2020-05-27
AU2014314214A1 (en) 2016-03-03
KR102497083B1 (ko) 2023-02-07
CA2920005A1 (en) 2015-03-05
JP2020180133A (ja) 2020-11-05
ES2742505T3 (es) 2020-02-14
CN117964710A (zh) 2024-05-03
CN105473606A (zh) 2016-04-06
MX367423B (es) 2019-08-21
US20160200772A1 (en) 2016-07-14
MX2016002208A (es) 2016-06-28
US9982022B2 (en) 2018-05-29
EP3039033B1 (en) 2019-06-19
DK3039033T3 (da) 2019-08-26
RU2016108976A (ru) 2017-10-04

Similar Documents

Publication Publication Date Title
HK1216756A1 (zh) 新的多肽
GB201311475D0 (en) Polypeptides
ZA201600721B (en) Binding polypeptides having a mutated scaffold
GB201322415D0 (en) A building block for a mechanical construction
SG11201602889TA (en) Novel polypeptides
GB201306726D0 (en) A glazing
PL3004010T3 (pl) Przeszklenie
GB201322417D0 (en) A building block for a mechanical construction
GB201317990D0 (en) A conncetor
EP3011117A4 (en) ROOF
HK1222422A1 (zh) 模板元件
GB201602351D0 (en) A building structure
GB201309421D0 (en) Polypeptides
ZA201506407B (en) New polypeptides
PL3080276T3 (pl) Polipeptydy toksyczne dla owadów
GB2506261B (en) A joint
GB201300656D0 (en) Building materials
GB201303977D0 (en) Binding polypeptides
GB201318941D0 (en) Novel polypeptides
GB2516914B (en) Tile
GB201311648D0 (en) A novel glass-lonomer cement
AU350587S (en) A batten
GB201403306D0 (en) Binding Polypeptides
GB201319398D0 (en) A footgauge
GB201316475D0 (en) A construction kit